The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Factors affecting the efficacy of COVID-19 vaccination in patients with AL amyloidosis
In this video, Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses some findings from a large prospective study which investigated the efficacy of COVID-19 vaccination in patients with light chain (AL) amyloidosis. Dr Kastritis explains the factors which affected antibody response in patients following vaccination, including the use of various therapies, such as daratumumab and bortezomib. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
